Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

ABSTRACT:

Purpose

Allogeneic hematopoietic cell transplantation (HCT) is curative but is associated with life-threatening complications. Most deaths occur within the first 2 years after transplantation. In this report, we examine long-term survival in 2-year survivors in the largest cohort ever studied.

Patients and methods

Records of 10,632 patients worldwide reported to the Center for International Blood and Marrow Transplant Research who were alive and disease free 2 years after receiving a myeloablative allogeneic HCT before 2004 for acute myelogenous or lymphoblastic leukemia, myelodysplastic syndrome, lymphoma, or severe aplastic anemia were reviewed.

Results

Median follow-up was 9 years, and 3,788 patients had been observed for 10 or more years. The probability of being

SUBMITTER: Wingard JR 

PROVIDER: S-EPMC3107742 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature